Because of the specificity of mutant IDH1 to tumor cells and its absence in the surrounding parenchyma, drugs specifically designed to disrupt mutant IDH1 may kill tumor cells with IDH1 mutations while sparing normal tissues. Here, IDH1 is linked to neoplasm.